Q2 26 EPS
$-1.95
Q2 26 Revenue
N/A
Est. $155.4M
vs S&P Since Q2 26
-6.5%
TRAILING MARKET
BNTX -4.5% vs S&P +2.0%
Market Reaction
Did BNTX Beat Earnings? Q2 2026 Results
BioNTech SE posted a narrower-than-hoped quarterly loss in Q2 2026, with adjusted earnings coming in at $-1.95 per share, missing the consensus estimate of $-1.92 by 1.62%, as the German biotech continues to absorb the costs of its sweeping pivot awa… Read more BioNTech SE posted a narrower-than-hoped quarterly loss in Q2 2026, with adjusted earnings coming in at $-1.95 per share, missing the consensus estimate of $-1.92 by 1.62%, as the German biotech continues to absorb the costs of its sweeping pivot away from COVID-19 vaccines toward a broad oncology platform. Revenue, against a consensus expectation of $155.38 million, reflected ongoing pressure from declining COVID-19 vaccine demand, with Q1 2026 IFRS revenues sliding to $118.00 million from $183.00 million a year ago, while the adjusted net loss widened to $495.00 million from $431.00 million in the prior-year period. The spending surge is deliberate, driven by $527.00 million in adjusted R&D outlays and more than 25 active Phase 2 and Phase 3 trials, including seven global registrational studies for pumitamig in partnership with Bristol Myers Squibb. Despite the stock sliding on the results, BioNTech reaffirmed full-year 2026 revenue guidance of $2.00 billion to $2.30 billion and pointed to $16.80 billion in cash and investments as proof of runway, while also initiating a $1.00 billion share repurchase program.
Key Takeaways
- • COVID-19 vaccine market leadership with over 50% share in key markets including Italy, Spain, France, Germany, USA, Japan, Australia
- • BMS partnership providing $3.5 billion upfront/non-contingent payments plus $7.6 billion in milestones
- • Over 5 billion vaccine doses distributed globally since 2020
BNTX Forward Guidance & Outlook
BioNTech reaffirmed full-year 2026 non-IFRS financial guidance: total revenues of €2.0–2.3 billion, adjusted R&D expenses of €2.2–2.5 billion, and adjusted SG&A expenses of €700–800 million. Revenue guidance considerations include competitive market dynamics in the United States, managing the transition away from multi-year COVID-19 vaccine contracts in Europe (particularly Germany), stable revenues from the BMS collaboration, a pandemic preparedness contract with the German government, and BioNTech Group service businesses. No operationally-driven one-time revenue effects are expected. The company targets 17+ late-stage/pivotal trial readouts through 2030+, aiming to become a diversified multi-product global immunotherapy company. Manufacturing footprint consolidation is expected to yield approximately €500 million in recurring annual savings upon full implementation by 2029. A share repurchase program of up to $1.0 billion has been initiated over the next twelve months.
BNTX Revenue by Segment
Business unit performance breakdown
BNTX Earnings Trends
BNTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BNTX EPS Trend
Earnings per share: estimate vs actual
BNTX Revenue Trend
Quarterly revenue: estimate vs actual
BNTX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 | — | $-1.95 | — | — | — |
| Q1 26 | $-2.14 | — | — | — | — |
| Q4 25 MISS FY | $-0.25 | $-1.25 | -405.66% | $907.4M | +24.34% |
| FY Full Year | $-3.44 | $-4.70 | -36.62% | $2.87B | +6.60% |
| Q3 25 MISS | $0.10 | $-0.12 | -220.36% | — | — |
| Q2 25 MISS | $-1.41 | $-1.85 | -31.65% | $301.6M | +14.39% |